Company page

Replimune Group, Inc.

Replimune Group, Inc. is a public biotechnology company based in America, focusing on developing innovative therapies for cancer treatment. The company is traded under the ticker REPL and has a market capitalization of approximately $841.4 million. Replimune is dedicated to advancing its research and clinical programs to improve patient outcomes in oncology.